Related references
Note: Only part of the references are listed.Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor
Yohei Saito et al.
CANCER SCIENCE (2008)
A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
T. Hamaguchi et al.
BRITISH JOURNAL OF CANCER (2007)
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors
Fumiaki Koizumi et al.
CANCER RESEARCH (2006)
Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
H Uchino et al.
BRITISH JOURNAL OF CANCER (2005)
NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
T Hamaguchi et al.
BRITISH JOURNAL OF CANCER (2005)
XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer
J Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
S Negoro et al.
BRITISH JOURNAL OF CANCER (2003)
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer
DC Bodurka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
W Noda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
